| scholarly article | Q13442814 |
| P50 | author | Gabriella Campadelli-Fiume | Q21062117 |
| Valentina Gatta | Q57123026 | ||
| Biljana Petrovic | Q57314115 | ||
| Laura Menotti | Q117248756 | ||
| Elisa Avitabile | Q124273094 | ||
| P2093 | author name string | Paolo Malatesta | |
| P2860 | cites work | Oncolytic viruses as therapeutic cancer vaccines | Q21245758 |
| The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells | Q24523691 | ||
| New viruses for cancer therapy: meeting clinical needs | Q24567699 | ||
| Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver | Q24633957 | ||
| Simple and highly efficient BAC recombineering using galK selection | Q24794075 | ||
| Retargeting Strategies for Oncolytic Herpes Simplex Viruses | Q26765439 | ||
| To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses | Q26767212 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. | Q30355682 | ||
| Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery | Q33479152 | ||
| Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. | Q33621028 | ||
| Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. | Q33730717 | ||
| Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells | Q33755158 | ||
| Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins | Q33812868 | ||
| Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas | Q33881165 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Breast tumor cell lines from pleural effusions | Q34209613 | ||
| The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy | Q34325749 | ||
| Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo | Q34464526 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. | Q34574879 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor | Q34600345 | ||
| A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors | Q34648103 | ||
| Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 | Q35060701 | ||
| Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV | Q35591421 | ||
| The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors | Q35638350 | ||
| ErbB receptors: directing key signaling networks throughout life | Q35639126 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Role of mannose-6-phosphate receptors in herpes simplex virus entry into cells and cell-to-cell transmission | Q35839774 | ||
| Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells | Q57009957 | ||
| The LNCaP cell line--a new model for studies on human prostatic carcinoma | Q71222674 | ||
| Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker | Q73889502 | ||
| Rescue and propagation of fully retargeted oncolytic measles viruses | Q81348398 | ||
| Transgenic models for prostate cancer research | Q83169251 | ||
| Absence of HeLa cell contamination in 169 cell lines derived from human tumors | Q41761715 | ||
| A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection | Q41806893 | ||
| TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma | Q42373489 | ||
| Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver | Q45289528 | ||
| Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. | Q45354666 | ||
| Construction and production of recombinant herpes simplex virus vectors | Q45392330 | ||
| Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand | Q45618074 | ||
| In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity | Q45756276 | ||
| The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1 | Q45805169 | ||
| Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells | Q45823697 | ||
| Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells | Q47562626 | ||
| Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors | Q47562637 | ||
| Single cell detection of latent cytomegalovirus reactivation in host tissue. | Q50545493 | ||
| Cancer-fighting viruses win approval. | Q50946428 | ||
| Long term culture of normal and neoplastic human glia. | Q51199195 | ||
| Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. | Q54466112 | ||
| Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma | Q35939421 | ||
| Construction and characterization of a herpes simplex virus type I recombinant expressing green fluorescent protein: acute phase replication and reactivation in mice | Q35989192 | ||
| How to develop viruses into anticancer weapons | Q36310887 | ||
| Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity | Q36321894 | ||
| Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases | Q36544212 | ||
| Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases | Q36546412 | ||
| Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility | Q36547314 | ||
| Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus | Q36659325 | ||
| Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. | Q36879211 | ||
| Viral therapy of glioblastoma multiforme | Q37031664 | ||
| Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma | Q37064326 | ||
| Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded | Q37191007 | ||
| Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells | Q37198935 | ||
| The EGFRvIII variant in glioblastoma multiforme | Q37424448 | ||
| Rethinking herpes simplex virus: the way to oncolytic agents | Q37882608 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe | Q38314192 | ||
| Local Delivery of OncoVEX(mGM-CSF) Generates Systemic Anti-Tumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade | Q38680081 | ||
| A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells | Q38714321 | ||
| Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle | Q38723279 | ||
| The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. | Q38819651 | ||
| Oncolytic viruses-immunotherapeutics on the rise | Q38919107 | ||
| Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. | Q39002223 | ||
| Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells | Q39036600 | ||
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
| Immune System, Friend or Foe of Oncolytic Virotherapy? | Q39355854 | ||
| Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer | Q39437344 | ||
| Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors | Q39735950 | ||
| Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. | Q39852211 | ||
| OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma | Q39866378 | ||
| Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. | Q39953338 | ||
| Genetics of natural resistance to herpesvirus infections in mice | Q39958787 | ||
| The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells | Q40144926 | ||
| Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation | Q40200208 | ||
| Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor | Q40350509 | ||
| Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. | Q40459690 | ||
| The herpes simplex virus JMP mutant enters receptor-negative J cells through a novel pathway independent of the known receptors nectin1, HveA, and nectin2. | Q40567844 | ||
| Noninvasive Monitoring of Glioma Growth in the Mouse. | Q41201141 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncolytic virus | Q1560099 |
| virology | Q7215 | ||
| P304 | page(s) | 352 | |
| P577 | publication date | 2018-06-30 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses | |
| P478 | volume | 10 |
| Q56348401 | A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors |
| Q91521080 | Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model |
| Q89682703 | Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy |
| Q63246477 | Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells |
| Q90171041 | Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis |
Search more.